Pilot study on the efficacy and safety of 0.01% atropine school children with progressive myopia in Hefei
10.16835/j.cnki.1000-9817.2021.02.004
- VernacularTitle:合肥城区进展性近视学龄儿童0.01%阿托品的疗效和安全性
- Author:
WANG Yong, JIANG Bo
1
Author Information
1. Department of Ophthalmology of Anhui NO. 2 Provincial People s Hospital，Hefei(230041),China
- Publication Type:期刊文章
- Keywords:
Myopia;
Atropine;
Intervention studies;
Child
- From:
Chinese Journal of School Health
2021;42(2):173-176
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical effict of 0.01% atropine for myopia progression in school children,and to provide a reference for probing into an effective methods of preventing myopia among children.
Methods:Thirty children, with a median age of 10 years (range 7-17), were given topical treatment with preservative free 0.01% atropine eye drops in both eyes before going to bed every night, and the efficacy and safety were analyzed 12 months later. Efficacy was assessed every 6 months. In 10 children, treatment of the second eye was delayed by one day to allow for a controlled safety assessment of side effects such as dilated pupils, hypoplasia and decreased myopia.
Results:In terms of myopia treatment, after 12 months of treatment with 0.01% atropine, it was 0.43 D/year(t=8.66，P<0.01). In terms of safety,in the 10 children s treatment of the second eye was delayed by one day, the measurable side effect was the induction of 1 mm pupil dilatation,and there was no other significant abnormalities were observed.
Conclusion:Topical low-dose (0.01%) atropine is safe and effective in school-age children,and it has certain clinical promotion value.
